Taysha Gene Therapies (TSHA) Cash from Investing Activities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Cash from Investing Activities for 4 consecutive years, with -$247000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 2000.0% to -$247000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$604000.0 through Dec 2025, down 66.39% year-over-year, with the annual reading at -$604000.0 for FY2025, 66.39% down from the prior year.
  • Cash from Investing Activities hit -$247000.0 in Q4 2025 for Taysha Gene Therapies, down from -$48000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $62000.0 in Q2 2025 to a low of -$11.4 million in Q1 2022.
  • Historically, Cash from Investing Activities has averaged -$2.1 million across 4 years, with a median of -$224000.0 in 2024.
  • Biggest five-year swings in Cash from Investing Activities: surged 230.0% in 2024 and later tumbled 2000.0% in 2025.
  • Year by year, Cash from Investing Activities stood at -$2.4 million in 2022, then soared by 99.58% to -$10000.0 in 2023, then soared by 230.0% to $13000.0 in 2024, then crashed by 2000.0% to -$247000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for TSHA at -$247000.0 in Q4 2025, -$48000.0 in Q3 2025, and $62000.0 in Q2 2025.